AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $261.19. The company's market cap stands at 462.81B, with a P/E ratio of 75.20 and a dividend yield of 2.57%.
During the trading session on 2026-08-20, AbbVie(ABBV) shares reached a daily high of $265.93 and a low of $260.48. At a current price of $261.19, the stock is +0.3% higher than the low and still -1.8% under the high.
Trading volume for AbbVie(ABBV) stock has reached 5.23M, versus its average volume of 4.57M.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
ABBV News
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...
The most widely read finance newsletter on Substack isn't published by a bank, it's Doomberg , where 383,000+ readers get the energy and macro analysis the main...
In recent weeks, AbbVie has highlighted the pending review of a subcutaneous induction option for SKYRIZI in Crohn’s disease, continued portfolio expansion thro...
Analyst ratings
75%
of 32 ratingsMore ABBV News
Piper Sandler raised the firm’s price target on AbbVie (ABBV) to $303 from $298 and keeps an Overweight rating on the shares. The firm notes monthly third-party...
Key Points Griffin first began buying AbbVie stock after its 2013 spinoff from Abbott Labs. AbbVie is in the process of spending $10.9 billion to buy Apogee T...
Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...
AbbVie (NYSE:ABBV) and Genmab reported that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab in diffuse large B-cell lymphoma did not meet its overall survival p...
Glenview Capital Management took new equity positions in Eli Lilly (LLY), with nearly 58K shares, and AbbVie (ABBV), with ~149K shares, according to the hedge f...
Key Points AbbVie demonstrates resilient revenue growth fueled by its next-generation immunology and aesthetics portfolio. Bristol-Myers Squibb maintains high...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident invest...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.